Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 4 |
Small molecule drug | 3 |
Top 5 Target | Count |
---|---|
CXCR4(C-X-C motif chemokine receptor 4) | 3 |
Target |
Mechanism CXCR4 antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date26 Apr 2024 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CXCR4 antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Mar 2024 |
Sponsor / Collaborator |
Start Date16 Oct 2020 |
Sponsor / Collaborator |
Start Date30 Apr 2020 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Mavorixafor ( CXCR4 ) | WHIM Syndrome More | NDA/BLA |
ASN-300 | Klebsiella pneumoniae infection More | Preclinical |
ASN-500 | Respiratory Syncytial Virus Infections More | Preclinical |
X4P-003 ( CXCR4 ) | Immunologic Deficiency Syndromes More | Preclinical |
X4P-002 ( CXCR4 ) | Glioblastoma Multiforme More | Preclinical |